Article

β-D-glucan Surveillance with Preemptive Anidulafungin for Invasive Candidiasis in Intensive Care Unit Patients: A Randomized Pilot Study

Department of Medicine and Pathology, University of Utah, Salt Lake City, Utah, United States of America.
PLoS ONE (Impact Factor: 3.53). 08/2012; 7(8):e42282. DOI: 10.1371/journal.pone.0042282
Source: PubMed

ABSTRACT Invasive candidiasis (IC) is a devastating disease. While prompt antifungal therapy improves outcomes, empiric treatment based on the presence of fever has little clinical impact. Β-D-Glucan (BDG) is a fungal cell wall component detectable in the serum of patients with early invasive fungal infection (IFI). We evaluated the utility of BDG surveillance as a guide for preemptive antifungal therapy in at-risk intensive care unit (ICU) patients.
Patients admitted to the ICU for ≥ 3 days and expected to require at least 2 additional days of intensive care were enrolled. Subjects were randomized in 3:1 fashion to receive twice weekly BDG surveillance with preemptive anidulafungin in response to a positive test or empiric antifungal treatment based on physician preference.
Sixty-four subjects were enrolled, with 1 proven and 5 probable cases of IC identified over a 2.5 year period. BDG levels were higher in subjects with proven/probable IC as compared to those without an IFI (117 pg/ml vs. 28 pg/ml; p<0.001). Optimal assay performance required 2 sequential BDG determinations of ≥ 80 pg/ml to define a positive test (sensitivity 100%, specificity 75%, positive predictive value 30%, negative predictive value 100%). In all, 21 preemptive and 5 empiric subjects received systemic antifungal therapy. Receipt of preemptive antifungal treatment had a significant effect on BDG concentrations (p< 0.001). Preemptive anidulafungin was safe and generally well tolerated with excellent outcome.
BDG monitoring may be useful for identifying ICU patients at highest risk to develop an IFI as well as for monitoring treatment response. Preemptive strategies based on fungal biomarkers warrant further study.
Clinical Trials.gov NCT00672841.

Download full-text

Full-text

Available from: Alfred Balch, Aug 24, 2015
0 Followers
 · 
134 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are increasing numbers of patients at risk for invasive fungal infections (IFI). The early diagnosis of IFI’s is limited by the lack of sensitivity and delayed turn-around time of routine cultures. Delays in diagnosis are associated with poor outcomes, especially with immunocompromised hosts and patients within the intensive care unit (ICU). Over the last decade, fungal biomarkers such as galactomannan and 1,3-β-D-glucan (BDG) have been increasingly utilized for the early and accurate diagnosis of these infections. This review will evaluate the recent clinical data on the BDG assay, focusing on its ability to assist in the diagnosis of invasive candidiasis in the ICU, and also whether BDG kinetics can predict the prognosis of the patient. Similarly, this review will evaluate BDG in invasive Aspergillus and Pneumocystis jiroveci diagnosis and prognosis, as well as the current limitations of the assay.
    Current Fungal Infection Reports 03/2012; 7(1). DOI:10.1007/s12281-012-0118-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infections present a great challenge in modern medicine. The recent devel-opment of serologic markers represents a clear advance in the field. Two serological tests have been developed: (1,3)-β-D glucan and Aspergillus galactomannan. This review discusses highlights of both tests.ResumenLas infecciones invasoras por hongos representan un gran reto para la medicina moderna. El reciente desarrollo de marcadores serológicos representa un claro avance en este campo. Se han desarrollados dos pruebas serológicas: (1,3)-β-d-glucano y galactomanano de Aspergillus. Esta revisión recoge los aspectos más destacados de cada una de las pruebas.
    12/2012; 16:59–63. DOI:10.1016/S0123-9392(12)70028-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: Blood cultures are limited for diagnosing invasive candidiasis by poor sensitivity and slow turn-around time. New diagnostics are needed to complement cultures, in particular to identify the "missing 50%" of patients who are blood culture-negative. Mannan/anti-mannan IgG, â-D-glucan (BDG) and PCR assays can diagnose candidemia before blood cultures and show promising sensitivity/specificity, but they are not widely-investigated in blood culture-negative, deep-seated candidiasis. In a recent study, BDG and PCR were superior to blood cultures in deep-seated candidiasis, suggesting they may identify currently-undiagnosed patients and expand our understanding of disease spectrum. Positive predictive values of non-culture tests are limited by the low prevalence of invasive candidiasis, which mandates that results be interpreted judiciously. Employed as biomarkers that assess a patient's risk of having invasive candidiasis, tests will facilitate pre-emptive antifungal strategies. Since negative predictive values are excellent, tests will also be useful for ruling-out invasive candidiasis and discontinuing unnecessary antifungal therapy.
    Clinical Infectious Diseases 01/2013; 56(9). DOI:10.1093/cid/cit006 · 9.42 Impact Factor
Show more